Technical Analysis for STX - Shield Therapeutics Plc

Grade Last Price % Change Price Change
F 1.33 -7.02% -0.10
STX closed down 7.02 percent on Wednesday, April 24, 2024, on 41 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Apr 25
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Extremely Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -7.02%
Lizard Bullish Bullish Day Trade Setup -7.02%
NR7 Range Contraction -7.02%
Narrow Range Bar Range Contraction -7.02%

   Recent Intraday Alerts

Alert Time
Down 5% about 6 hours ago
Down 1 ATR about 6 hours ago
Fell Below Previous Day's Low about 10 hours ago
Down 3% about 10 hours ago
Down 2% about 10 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Shield Therapeutics Plc Description

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Pharmaceuticals Disease Pipe Clinic Hospital Pharmaceutical Industry Clinical Trial Blood Phosphate Clinical Research Inflammatory Bowel Disease Design Of Experiments Kidney Disease Chronic Kidney Disease Hypophosphatemia

Is STX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.85
52 Week Low 1.3005
Average Volume 7,129,224
200-Day Moving Average 6.51
50-Day Moving Average 2.50
20-Day Moving Average 1.65
10-Day Moving Average 1.48
Average True Range 0.12
RSI (14) 11.50
ADX 77.52
+DI 3.02
-DI 40.73
Chandelier Exit (Long, 3 ATRs) 1.84
Chandelier Exit (Short, 3 ATRs) 1.66
Upper Bollinger Bands 2.09
Lower Bollinger Band 1.22
Percent B (%b) 0.12
BandWidth 52.60
MACD Line -0.33
MACD Signal Line -0.38
MACD Histogram 0.047
Fundamentals Value
Market Cap 10.36 Million
Num Shares 782 Million
EPS -0.12
Price-to-Earnings (P/E) Ratio -11.04
Price-to-Sales 6.29
Price-to-Book 1.67
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.51
Resistance 3 (R3) 1.52 1.47 1.48
Resistance 2 (R2) 1.47 1.43 1.47 1.47
Resistance 1 (R1) 1.40 1.40 1.38 1.39 1.46
Pivot Point 1.35 1.35 1.34 1.34 1.35
Support 1 (S1) 1.28 1.30 1.25 1.26 1.19
Support 2 (S2) 1.23 1.27 1.22 1.18
Support 3 (S3) 1.15 1.23 1.17
Support 4 (S4) 1.14